Bristol-myers Squibb Compnay

Medimmune Limited

Emergent Product Development Seattle,llc

Aptevo Research and Development LLC

Pfizer Corporation

Ambrx, Inc.

William Brady

Jeffrey A Ledbetter

Peter S Linsley

Nitin Krishnaji Damle

Martha Susan Hayden-Ledbetter

Peter Armstrong Thompson

Peter A Kiener

Sandy Alexander Simon

Kenneth H Grabstein

Philip M Wallace

Laura Sue Grosmaire

Robert Peach

Jurgen Bajorath

Jeffrey C Johnson

Michael Van Brunt

Philip Tan

Marcello Marelli

Cecile Morales

Leslie Sydnor Johnson

Paul A Moore

Lioudmila Tchistiakova

Feng Tian

Lidia Mosyak

Gordon E King

Natalie Winblade Nairn

Jianing Wang

Charles G Cerveny

Adam Reid Root

Laird Bloom

Andrea Wang

Chad Michael May

Gordon King

Shivarupam Bhowmik

Jinming Xia

Christy Anne Nilsson

Robert Bader

Kurt David Shanebeck

Paul Heffner Slagle

Kenneth Christopher Thornton

Michael Peter Vanbrunt

Hengyu Xu

Valerie Calabro

Maximillian T Follettie

Alwin Schuler

Robert J Peach

Jeffrey Johnson

The invention relates to prostate specific membrane antigen humanized antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.

Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.

CD37 immunotherapeutics and uses thereof

There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Cell lines

The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.

Antibody derivatives

B-cell reduction using CD37-specific and CD20-specific binding molecules

Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.

Bispecific heterodimeric diabodies and uses thereof

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.

CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof

Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.

Single chain multivalent binding proteins with effector function

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

Soluble CTLA4 mutant molecules

Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions

The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.

Soluble CTLA4 mutant molecules and uses thereof

The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. The invention further provides methods for using antibodies to B7, or fragments thereof, to regulate CD28 positive T cell response and immune responses mediated by T cells.

Methods for blocking binding of CD28 receptor to B7

This invention provides methods for regulating T cell interactions with B7 positive cells. Methods are provided for using B7 antigen, its fragments and derivatives reactive with CTLA4 receptor, to regulate CTLA4 positive T cell responses, and immune responses mediated by T cells.

Method to inhibit T cell interactions with soluble B7

Growing community of inventors

Bothell, WA, United States of America

William Brady